Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Quizartinib Monotherapy in Japanese FLT3-ITD Positive R/R AML
jRCT2080223386Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Efficacy - blast count reduction. Started Nov 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223386.